{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T02:04:00Z","timestamp":1775700240568,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The 30-day readmission rate after hospitalization for a sickle cell crisis (SCC) is extremely high. Accurate information on readmission diagnoses, total readmission costs and factors associated with readmission is required to effectively plan resource allocation and to plan interventions to reduce readmission rates. The present study aimed to examine readmission diagnoses and factors associated with all-cause 30-day readmission after hospitalization for SCC. We analyzed 2016 nationwide readmission database (NRD) to identify patterns of 30-day readmission by patient demographic characteristics and time after hospitalization for SCC. We estimated the percentage and most common readmission diagnoses for 30-day and 7-day readmissions after discharge. We studied the relationship between risk factors and readmission and the impact of readmission on patient outcomes and resulting financial burden on health care in dollars. In 2016, of 67,887 discharges after index hospitalizations, 18099 (26.9%) were readmitted within 30-days. Of all readmissions, 5166 (7.6%) were readmitted within 7 days. The spectrum of readmission diagnoses was largely similar in both 30-day and 7-day readmission with more than 80% patients in both time periods readmitted with diagnoses related to SCC. The mean length of stay for readmitted patients was significantly longer than the index hospitalization (5.3 days (5.1\u20135.5) vs 4.9 days (CI 4.8\u20135.1, p\u2009&lt;\u20090.01). Also, the mean cost of hospitalization in readmitted patients $8485 was significantly higher than the index hospitalization $8064 p\u2009&lt;\u20090.01. In 2016, readmission among patients with SCC incurred an additional 95,445 hospitalization days resulting a total charge of $609 million and a total cost of $152 million in the US. On Multivariate analysis, age group 18\u201330 years, discharge against medical advice, higher Charlson comorbidity index, low socioeconomic status and admission at high volume centers were associated with a higher likelihood of 30-day readmission. Among patients hospitalized for SCC, 30-day readmissions were frequent throughout the month post hospitalization and resulted in an enormous financial burden on the United States healthcare system.<\/jats:p>","DOI":"10.1038\/s41598-020-58934-3","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T11:03:42Z","timestamp":1581073422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Epidemiology and Predictors of all-cause 30-Day readmission in patients with sickle cell crisis"],"prefix":"10.1038","volume":"10","author":[{"given":"Vivek","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen M.","family":"Achebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"issue":"14","key":"58934_CR1","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1056\/NEJMsa0803563","volume":"360","author":"SF Jencks","year":"2009","unstructured":"Jencks, S. F., Williams, M. V. & Coleman, E. A. Rehospitalizations among patients in the Medicare fee-for-service program. N. Engl. J. Med. 360(14), 1418\u201328 (2009).","journal-title":"N. Engl. J. Med."},{"key":"58934_CR2","unstructured":"Why Not the Best? Results from the National Scorecard on U.S. Health System Performance, 2011 | Commonwealth Fund 2011 [Available from: https:\/\/www.commonwealthfund.org\/publications\/fund-reports\/2011\/oct\/why-not-best-results-national-scorecard-us-health-system."},{"key":"58934_CR3","unstructured":"Why Not the Best? Results from the National Scorecard on U.S. Health System Performance, 2011 | Commonwealth Fund 2019 [Available from: https:\/\/www.commonwealthfund.org\/publications\/fund-reports\/2011\/oct\/why-not-best-results-national-scorecard-us-health-system."},{"issue":"(4 Suppl)","key":"58934_CR4","doi-asserted-by":"publisher","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","volume":"38","author":"KL Hassell","year":"2010","unstructured":"Hassell, K. L. Population estimates of sickle cell disease in the U.S. Am. J. Prev. Med. 38((4 Suppl)), S512\u201321 (2010).","journal-title":"Am. J. Prev. Med."},{"issue":"13","key":"58934_CR5","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","volume":"289","author":"MH Steinberg","year":"2003","unstructured":"Steinberg, M. H. et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 289(13), 1645\u201351 (2003).","journal-title":"JAMA."},{"issue":"24","key":"58934_CR6","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMp1901225","volume":"380","author":"RK Wadhera","year":"2019","unstructured":"Wadhera, R. K., Yeh, R. W. & Joynt Maddox, K. E. The Hospital Readmissions Reduction Program-Time for a Reboot. N. Engl. J. Med. 380(24), 2289\u201391. (2019).","journal-title":"N. Engl. J. Med."},{"key":"58934_CR7","unstructured":"Readmissions-Reduction-Program 2019 [updated 01\/16\/2019 6:39 AM. Available from: https:\/\/www.cms.gov\/medicare\/medicare-fee-for-service-payment\/acuteinpatientpps\/readmissions-reduction-program.html."},{"issue":"13","key":"58934_CR8","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1001\/jama.2010.378","volume":"303","author":"DC Brousseau","year":"2010","unstructured":"Brousseau, D. C., Owens, P. L., Mosso, A. L., Panepinto, J. A. & Steiner, C. A. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 303(13), 1288\u201394 (2010).","journal-title":"JAMA."},{"issue":"1","key":"58934_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ajh.20336","volume":"79","author":"SK Ballas","year":"2005","unstructured":"Ballas, S. K. & Lusardi, M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am. J. Hematol. 79(1), 17\u201325 (2005).","journal-title":"Am. J. Hematol."},{"issue":"(5)","key":"58934_CR10","doi-asserted-by":"publisher","first-page":"601 e9","DOI":"10.1016\/j.amjmed.2016.12.010","volume":"130","author":"MA Brodsky","year":"2017","unstructured":"Brodsky, M. A. et al. Risk Factors for 30-Day Readmission in Adults with Sickle Cell Disease. Am. J. Med. 130((5)), 601 e9\u2013e15 (2017).","journal-title":"Am. J. Med."},{"issue":"2","key":"58934_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.5811\/westjem.2017.9.35422","volume":"19","author":"DM Cline","year":"2018","unstructured":"Cline, D. M., Silva, S., Freiermuth, C. E., Thornton, V. & Tanabe, P. Emergency Department (ED), ED Observation, Day Hospital, and Hospital Admissions for Adults with Sickle Cell Disease. West. J. Emerg. Med. 19(2), 311\u20138 (2018).","journal-title":"West. J. Emerg. Med."},{"issue":"1","key":"58934_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/16078454.2018.1549801","volume":"24","author":"RM Cronin","year":"2019","unstructured":"Cronin, R. M. et al. Risk factors for hospitalizations and readmissions among individuals with sickle cell disease: results of a U.S. survey study. Hematology. 24(1), 189\u201398. (2019).","journal-title":"Hematology."},{"issue":"4","key":"58934_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/pbc.21854","volume":"52","author":"MJ Frei-Jones","year":"2009","unstructured":"Frei-Jones, M. J., Field, J. J. & DeBaun, M. R. Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease. Pediatric blood cancer. 52(4), 481\u20135 (2009).","journal-title":"Pediatric blood cancer."},{"issue":"3","key":"58934_CR14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/pbc.23140","volume":"58","author":"J Leschke","year":"2012","unstructured":"Leschke, J. et al. Outpatient follow-up and rehospitalizations for sickle cell disease patients. Pediatr. Blood Cancer. 58(3), 406\u20139 (2012).","journal-title":"Pediatr. Blood Cancer."},{"key":"58934_CR15","unstructured":"THE HCUP NATIONWIDE READMISSIONS DATABASE (NRD), 2010-2016 2019 [Available from: https:\/\/www.hcup-us.ahrq.gov\/db\/nation\/nrd\/Introduction_NRD_2010-2016.jsp."},{"key":"58934_CR16","doi-asserted-by":"crossref","unstructured":"Gerhardt G, et al Medicare readmission rates showed meaningful decline in 2012. Medicare Medicaid Res Rev. 3(2) (2013).","DOI":"10.5600\/mmrr.003.02.b01"},{"key":"58934_CR17","unstructured":"Free 2019 ICD-10-CM Codes-ICD-10 Data https:\/\/www.icd10data.com\/ICD10CM\/Codes-Google Search2019. Available from: https:\/\/www.google.com\/search?q=Free+2019+ICD-10-CM+Codes+-+ICD 10+Data+https%3A%2F%2FError! Hyperlink reference not valid."},{"issue":"10","key":"58934_CR18","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1089\/wound.2013.0478","volume":"2","author":"DJ Cartwright","year":"2013","unstructured":"Cartwright, D. J. ICD-9-CM to ICD-10-CM Codes: What? Why? How? Adv. Wound Care. 2(10), 588\u201392 (2013).","journal-title":"Adv. Wound Care."},{"issue":"7","key":"58934_CR19","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1001\/jamainternmed.2014.1608","volume":"174","author":"AL Leppin","year":"2014","unstructured":"Leppin, A. L. et al. Preventing 30-day hospital readmissions: a systematic review and meta-analysis of randomized trials. JAMA Intern. Med. 174(7), 1095\u2013107 (2014).","journal-title":"JAMA Intern. Med."},{"issue":"4","key":"58934_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1001\/jama.2012.216476","volume":"309","author":"K Dharmarajan","year":"2013","unstructured":"Dharmarajan, K. et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 309(4), 355\u201363 (2013).","journal-title":"JAMA."},{"issue":"5","key":"58934_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.hrtlng.2017.06.005","volume":"46","author":"KA Mirkin","year":"2017","unstructured":"Mirkin, K. A., Enomoto, L. M., Caputo, G. M. & Hollenbeak, C. S. Risk factors for 30-day readmission in patients with congestive heart failure. Heart Lung. 46(5), 357\u201362 (2017).","journal-title":"Heart Lung."},{"issue":"1","key":"58934_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1053\/j.gastro.2018.03.033","volume":"155","author":"MS Abougergi","year":"2018","unstructured":"Abougergi, M. S., Peluso, H. & Saltzman, J. R. Thirty-Day Readmission Among Patients With Non-Variceal Upper Gastrointestinal Hemorrhage and Effects on Outcomes. Gastroenterology. 155(1), 38\u201346 e1 (2018).","journal-title":"Gastroenterology."},{"issue":"6","key":"58934_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/ajh.21408","volume":"84","author":"TL Kauf","year":"2009","unstructured":"Kauf, T. L., Coates, T. D., Huazhi, L., Mody-Patel, N. & Hartzema, A. G. The cost of health care for children and adults with sickle cell disease. Am. J. Hematol. 84(6), 323\u20137 (2009).","journal-title":"Am. J. Hematol."},{"issue":"6","key":"58934_CR24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ajh.21443","volume":"84","author":"SK Ballas","year":"2009","unstructured":"Ballas, S. K. The cost of health care for patients with sickle cell disease. Am. J. Hematol. 84(6), 320\u20132 (2009).","journal-title":"Am. J. Hematol."},{"key":"58934_CR25","doi-asserted-by":"crossref","unstructured":"Manwani D, Carullo V, Rinke M, Choi S, Driscoll C. Reducing Health Care Utilization in Sickle Cell Disease Patients By Implementation of an Individualized, Multimodal Care Plan during Hospital Admission and at Inpatient to Outpatient Discharge. Am Soc Hematology; (2014).","DOI":"10.1182\/blood.V124.21.444.444"},{"key":"58934_CR26","doi-asserted-by":"crossref","unstructured":"Morrone, K. A. et al. Decreased Hospital Readmissions for Vaso Occlusive Crisis with Implementation of a Sickle Cell Pain Action Plan (SPAP). Am Soc Hematology, 2017.","DOI":"10.1182\/blood.V130.Suppl_1.867.867"},{"issue":"(1)","key":"58934_CR27","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.1002\/ajh.25311","volume":"94","author":"J Han","year":"2019","unstructured":"Han, J. et al. High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease. Am. J. hematology. 94((1)), E5\u2013E7 (2019).","journal-title":"Am. J. hematology."},{"key":"58934_CR28","doi-asserted-by":"crossref","unstructured":"Okorji LM, Muntz DS, Liem RI. Opioid prescription practices at discharge and 30-day returns in children with sickle cell disease and pain. Pediatr Blood Cancer; 64(5) (2017).","DOI":"10.1002\/pbc.26319"},{"issue":"11","key":"58934_CR29","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M14-2159","volume":"162","author":"KL Graham","year":"2015","unstructured":"Graham, K. L., Wilker, E. H., Howell, M. D., Davis, R. B. & Marcantonio, E. R. Differences between early and late readmissions among patients: a cohort study. Ann. Intern. medicine. 162(11), 741\u20139 (2015).","journal-title":"Ann. Intern. medicine."},{"key":"58934_CR30","doi-asserted-by":"crossref","unstructured":"Telfair, J., Ehiri, J. \u0395., Loosier, P. S., Baskin, M. L. Transition to adult care for adolescents with sickle cell disease: results of a national survey. De Gruyter; (2004).","DOI":"10.1515\/IJAMH.2004.16.1.47"},{"issue":"6","key":"58934_CR31","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ajh.22016","volume":"86","author":"A Sobota","year":"2011","unstructured":"Sobota, A., Neufeld, E. J., Sprinz, P. & Heeney, M. M. Transition from pediatric to adult care for sickle cell disease: results of a survey of pediatric providers. Am. J. Hematol. 86(6), 512\u20135 (2011).","journal-title":"Am. J. Hematol."},{"issue":"1","key":"58934_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jana.2016.10.002","volume":"28","author":"D Alfandre","year":"2017","unstructured":"Alfandre, D. et al. \u201cAgainst Medical Advice\u201d Discharges Among HIV-Infected Patients: Health and Health Services Outcomes. J. Assoc. Nurses AIDS Care. 28(1), 95\u2013104 (2017).","journal-title":"J. Assoc. Nurses AIDS Care."},{"issue":"5","key":"58934_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/jhm.643","volume":"5","author":"C Haywood Jr","year":"2010","unstructured":"Haywood, C. Jr et al. Hospital self\u2010discharge among adults with sickle-cell disease (SCD): Associations with trust and interpersonal experiences with care. J. hospital medicine. 5(5), 289\u201394 (2010).","journal-title":"J. hospital medicine."},{"issue":"4-5","key":"58934_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/13557858.2011.555520","volume":"16","author":"J Elander","year":"2011","unstructured":"Elander, J., Beach, M. C. & Haywood, C. Jr. Respect, trust, and the management of sickle cell disease pain in hospital: comparative analysis of concern-raising behaviors, preliminary model, and agenda for international collaborative research to inform practice. Ethn. Health. 16(4-5), 405\u201321 (2011).","journal-title":"Ethn. Health."},{"issue":"2","key":"58934_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jpainsymman.2003.12.001","volume":"27","author":"J Elander","year":"2004","unstructured":"Elander, J., Lusher, J., Bevan, D., Telfer, P. & Burton, B. Understanding the causes of problematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. J. pain. symptom management. 27(2), 156\u201369 (2004).","journal-title":"J. pain. symptom management."},{"issue":"10","key":"58934_CR36","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jama.2014.10517","volume":"312","author":"BP Yawn","year":"2014","unstructured":"Yawn, B. P. et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 312(10), 1033\u201348 (2014).","journal-title":"JAMA."},{"issue":"3","key":"58934_CR37","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jpainsymman.2015.11.004","volume":"51","author":"AP Singh","year":"2016","unstructured":"Singh, A. P. et al. Improving emergency providers\u2019 attitudes toward sickle cell patients in pain. J. pain. symptom management. 51(3), 628\u201332. e3 (2016).","journal-title":"J. pain. symptom management."},{"issue":"3","key":"58934_CR38","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0885-3924(97)00019-5","volume":"14","author":"BS Shapiro","year":"1997","unstructured":"Shapiro, B. S., Benjamin, L. J., Payne, R. & Heidrich, G. Sickle cell-related pain: perceptions of medical practitioners. J. Pain. Symptom Manage. 14(3), 168\u201374 (1997).","journal-title":"J. Pain. Symptom Manage."},{"issue":"9-10","key":"58934_CR39","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0027-9684(15)30199-1","volume":"104","author":"J Porter","year":"2012","unstructured":"Porter, J., Feinglass, J., Artz, N., Hafner, J. & Tanabe, P. Sickle cell disease patients\u2019 perceptions of emergency department pain management. J. Natl Med. Assoc. 104(9-10), 449\u201354 (2012).","journal-title":"J. Natl Med. Assoc."},{"issue":"2","key":"58934_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.15171\/ijhpm.2013.25","volume":"1","author":"K Noohi","year":"2013","unstructured":"Noohi, K., Komsari, S., Nakhaee, N. & Yazdi Feyzabadi, V. Reasons for Discharge against Medical Advice: A Case Study of Emergency Departments in Iran. Int. J. Health Policy Manag. 1(2), 137\u201342 (2013).","journal-title":"Int. J. Health Policy Manag."},{"issue":"4","key":"58934_CR41","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/082585970502100403","volume":"21","author":"E Labbe","year":"2005","unstructured":"Labbe, E., Herbert, D. & Haynes, J. Physicians\u2019 attitude and practices in sickle cell disease pain management. J. Palliat. Care. 21(4), 246\u201351 (2005).","journal-title":"J. Palliat. Care."},{"issue":"4","key":"58934_CR42","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/pubmed\/fdt100","volume":"35","author":"G Aljuburi","year":"2013","unstructured":"Aljuburi, G. et al. Socio-economic deprivation and risk of emergency readmission and inpatient mortality in people with sickle cell disease in England: observational study. J. Public. Health. 35(4), 510\u20137 (2013).","journal-title":"J. Public. Health."},{"issue":"2","key":"58934_CR43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1056\/NEJMp1212324","volume":"368","author":"HM Krumholz","year":"2013","unstructured":"Krumholz, H. M. Post-hospital syndrome\u2013an acquired, transient condition of generalized risk. N. Engl. J. Med. 368(2), 100\u20132 (2013).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"58934_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jped.2016.07.005","volume":"93","author":"A Fernandes","year":"2017","unstructured":"Fernandes, A., Avendanha, F. A. & Viana, M. B. Hospitalizations of children with sickle cell disease in the Brazilian Unified Health System in the state of Minas Gerais. J. Pediatr. 93(3), 287\u201393 (2017).","journal-title":"J. Pediatr."},{"key":"58934_CR45","doi-asserted-by":"crossref","unstructured":"Onimoe, G. I., Carlson, A., Frazier, R., Bartley, R., Feldman, E. Aiming to Reduce Admissions and Also Re-Admissions in Pediatric Sickle Cell Disease: A Single Institutional Experience with Six Interventions. Am Soc Hematology; (2016).","DOI":"10.1182\/blood.V128.22.5920.5920"},{"key":"58934_CR46","doi-asserted-by":"publisher","first-page":"h447","DOI":"10.1136\/bmj.h447","volume":"350","author":"LI Horwitz","year":"2015","unstructured":"Horwitz, L. I. et al. Association of hospital volume with readmission rates: a retrospective cross-sectional study. BMJ. 350, h447 (2015).","journal-title":"BMJ."},{"issue":"11","key":"58934_CR47","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/jhm.2271","volume":"9","author":"L Horwitz","year":"2014","unstructured":"Horwitz, L. The insurance\u2013readmission paradox: Why increasing insurance coverage may not reduce hospital-level readmission rates. J. hospital medicine. 9(11), 743\u20134 (2014).","journal-title":"J. hospital medicine."},{"key":"58934_CR48","doi-asserted-by":"crossref","unstructured":"Klabunde, C. N., Warren J. L., Legler, J. M. Assessing comorbidity using claims data: an overview. Medical care. IV26\u2013IV35 (2002).","DOI":"10.1097\/00005650-200208001-00004"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58934-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58934-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58934-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T06:29:48Z","timestamp":1670308188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58934-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["58934"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-58934-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"14 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Vivek Kumar No, I declare that I have no competing interests as defined by Nature Research, or other interests that might be perceived to influence the results and\/or discussion reported in this paper. Neha Chaudhary No, I declare that I have no competing interests as defined by Nature Research, or other interests that might be perceived to influence the results and\/or discussion reported in this paper. Maureen Achebe None No, I declare that I have no competing interests as defined by Nature Research, or other interests that might be perceived to influence the results and\/or discussion reported in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2082"}}